Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling

Allanson, 2011, Cardio-facio-cutaneous syndrome: does genotype predict phenotype?, Am. J. Med. Genet. C. Semin. Med. Genet., 157, 129, 10.1002/ajmg.c.30295

Dougherty, 2005, Regulation of Raf-1 by direct feedback phosphorylation, Mol. Cell, 17, 215, 10.1016/j.molcel.2004.11.055

Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969

Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N. Engl. J. Med., 363, 809, 10.1056/NEJMoa1002011

Gaestel, 2009, Peptides as signaling inhibitors for mammalian MAP kinase cascades, Curr. Pharm. Des., 15, 2471, 10.2174/138161209788682299

Garnett, 2005, Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization, Mol. Cell, 20, 963, 10.1016/j.molcel.2005.10.022

Hatzivassiliou, 2010, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, 464, 431, 10.1038/nature08833

Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040

Marais, 1997, Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases, J. Biol. Chem., 272, 4378, 10.1074/jbc.272.7.4378

Nazarian, 2010, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, 468, 973, 10.1038/nature09626

Pandit, 2007, Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy, Nat. Genet., 39, 1007, 10.1038/ng2073

Poulikakos, 2011, RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, 480, 387, 10.1038/nature10662

Pritchard, 1995, Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells, Mol. Cell. Biol., 15, 6430, 10.1128/MCB.15.11.6430

Rajakulendran, 2009, A dimerization-dependent mechanism drives RAF catalytic activation, Nature, 461, 542, 10.1038/nature08314

Ritt, 2010, Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling, Mol. Cell. Biol., 30, 806, 10.1128/MCB.00569-09

Rodriguez-Viciana, 2006, Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome, Science, 311, 1287, 10.1126/science.1124642

Röring, 2012, Aberrant B-Raf signaling in human cancer — 10 years from bench to bedside, Crit. Rev. Oncog., 17, 97, 10.1615/CritRevOncog.v17.i1.70

Röring, 2012, Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling, EMBO J., 31, 2629, 10.1038/emboj.2012.100

Rushworth, 2006, Regulation and role of Raf-1/B-Raf heterodimerization, Mol. Cell. Biol., 26, 2262, 10.1128/MCB.26.6.2262-2272.2006

Su, 2012, Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation, Cancer Res., 72, 969, 10.1158/0008-5472.CAN-11-1875

Tartaglia, 2011, Noonan syndrome and clinically related disorders, Best Pract. Res. Clin. Endocrinol. Metab., 25, 161, 10.1016/j.beem.2010.09.002

Wan, 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 855, 10.1016/S0092-8674(04)00215-6

Weber, 2001, Active Ras induces heterodimerization of cRaf and BRaf, Cancer Res., 61, 3595

Wellbrock, 2004, The RAF proteins take centre stage, Nat. Rev. Mol. Cell Biol., 5, 875, 10.1038/nrm1498